title: The effect of methylprednisolone on treatment in rats with induced sepsis.
abstract: In this study, an appropriate sepsis model was created in rats. Additionally, the effects of steroid treatments on survival, in connection with antibiotic treatment, were investigated. The sepsis model performed via intraperitoneal injection of 3 ml/kg fecal suspension was determined as the most appropriate model for our study. Fifteen rats were used to investigate the effect of piperacillin-tazobactam on sepsis treatment. Forty-five randomly selected rats were used to investigate the efficacy of the antibiotic-plus-steroid combination. The rats were divided into three groups of 15 rats each. Twelve hours after the administration of fecal suspension, methylprednisolone (MP) at the dose of 0.25, 0.5, and 2 mg/kg/day was given to each group, respectively, in addition to an antibiotic administered intravenously. In order to investigate the effect of steroids alone in the treatment of sepsis, 0.5 mg/kg/day MP was given intravenously to 15 rats, 12 h after the fecal suspension was administered. It was concluded that administration of MP alone shortens survival time in rats with sepsis, whereas antibiotic therapy alone increases survival time significantly in rats with sepsis. It was seen that the antibiotic-plus-steroid treatment increases survival significantly compared to rats with no treatment (p < 0.05). In addition, steroids, when added to an antibiotic treatment in sepsis, affect survival positively when compared to the group with antibiotic therapy alone, depending on the dose given. Although, not statistically significant, high doses decrease survival (p > 0.05), and very low doses increase survival and mean survival time (p > 0.05) on the basis of clinical observation and average life time. However, low doses were found to increase survival significantly (p < 0.05). We concluded that low-dose MP, in addition to the appropriate antibiotic therapy, is the optimal in the treatment of rats with intraabdominal sepsis.
authors.affiliation: Infectious Diseases and Clinical Microbiology Clinic, Derince Military Hospital, Kocaeli, Turkey.
authors.forename: Riza Aytaç
authors.initials: RA
authors.lastname: Cetinkaya
authors.forename: Levent
authors.initials: L
authors.lastname: Görenek
authors.forename: Omer
authors.initials: O
authors.lastname: Coşkun
authors.forename: Can Polat
authors.initials: CP
authors.lastname: Eyigün
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Senses
authors.forename: Tayfun
authors.initials: T
authors.lastname: Ide
authors.forename: Selim
authors.initials: S
authors.lastname: Kiliç
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D008775:Methylprednisolone / Q000627:therapeutic use*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000188:drug therapy*
chemical_list: D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; D008775:Methylprednisolone